Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of PledOx plus FOLFOX6 in metastatic colorectal cancer
2012-001367-76Phase 2Completed
- Sponsor
- Egetis Therapeutics
- Start
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of calmangafodipir in metastatic colorectal adenocarcinoma (mCRC) (3 arms), sponsored by Egetis Therapeutics. Primary endpoint: Neutropenia grade 3 and 4. Started Jun 2012; status: completed.
02
Drugs
calmangafodipir
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2012-001367-76.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001367-76.